CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache by Tfelt-Hansen, Peer Carsten
REVIEW ARTICLE
CONSORT recommendations in abstracts of randomised,
controlled trials on migraine and headache
Peer Carsten Tfelt-Hansen
Received: 5 May 2011/Accepted: 10 June 2011/Published online: 28 June 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract A CONSORT statement on the content of
abstracts of randomised, controlled trials (RCTs) was pub-
lished in 2008. I therefore reviewed the abstracts from 2009
to 2010 published on RCTs in Cephalalgia, Headache and
other (non-headache) journals. The following items were
reviewed: number of patients, reporting of response either
in percentages or absolute values, the use of p values, and
effect size with its precision. The latter was recommended
in the CONSORT statement. A total of 46 abstracts were
reviewed and effect size with 95% conﬁdence intervals was
only reported in seven abstracts. The inﬂuence of the
CONSORT statement on reporting in abstracts has so far
only had a limited inﬂuence on the headache literature.
Keywords CONSORT statement  Migraine  Treatment 
Randomised  Clinical trials
‘‘For clinical trials, clear, transparent, and sufﬁ-
ciently, detailed abstracts of journal articles and
conference abstracts are important because readers
often base their, assessment of a trial on such infor-
mation’’ Hopewell et al. [1].
Introduction
As explained in the vignette, the abstract is an important
part of the publication of a randomised, controlled trial
(RCT). In 2008, the CONSORT group published a state-
ment on reporting RCTs in journal and conference
abstracts [1], see Table 1.
I therefore wanted to investigate whether this CON-
SORT statement has had an impact on the literature on
RCTs in migraine and headache treatment. The years 2009
and 2010 were chosen as the appropriate years to evaluate
this question. The CONSORT statement for abstract is very
demanding (see Table 1) and I therefore chose to review
only the most important efﬁcacy items (in italics in
Table 1).
Methods
The three headache journals, Cephalalgia, Headache and
Journal of Headache and Pain, were hand-searched twice
for RCTs in 2009 and 2010. In addition, PubMed was
searched for RCTs in other journals in 2009 and 2010 with
the search terms: ‘‘migraine’’, ‘‘treatment’’ and ‘‘clinical
trial’’ as well as ‘‘headache’’, ‘‘treatment’’ and ‘‘clinical
trial’’. The abstracts were rated for the presence of numbers
in each treatment group or total number of patients, per-
centage response or absolute values for response, p values,
absolute effect size (percentage responding in active
treatment group minus percentage responding in control
group) and 95% conﬁdence intervals (95% CI) for absolute
effect size (see Tables 2, 3 and 4).
Results
In Cephalalgia, 17 abstracts on RCTs (Table 2)[ 2–18] and
in Headache 13 abstracts on RCTs were found (Table 3)
[19–31]. In the Journal of Headache and Pain, only one
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reporting of randomised trials in
journal or conference abstracts
[1]
a For conference abstracts
Item Description
Title Identiﬁcation of the study as randomised
Authors
a Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster, non-inferiority)
Methods
Participants Eligibility criteria for participants and the settings in which the data were collected
Interventions Interventions intended for each group
Objective Speciﬁc objective or hypothesis
Outcome Clearly deﬁned primary outcome for this report
Randomisation How participants were allocated to interventions
Blinding
(masking)
Whether or not participants, care givers and those assessing the outcomes were








Number of participants analysed in each group
Outcome For the primary outcome, a result for each group and the estimated effect size and its
precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
Table 2 Presentation in
abstracts concerning efﬁcacy in
double-blind, randomised,
controlled trials (RCTs) in
Cephalalgia in 2009 and 2010
CO crossover
a Pooled results of 2 RCTs





p values Effect size 95% CI for
effect size
2010
[2] 37/37/38 – – – –
[3] (1677) – ? ––
[4]4 2 C O – ? ––
[5] 343/347 ?? ––
[6] 88/42 ?? ––
[7] (117) ?? ––
[8]3 0 C O A V ? ––
[9] 347/358 AV ? ––
[10] 341/338 AV ? ––
[11] (27) – – – –
2009
[12]– – – – –
[13] (859) ? –– –
[14] (410) AV ? ––
[15] (95) AV ? ––
[16] 1135/846
a ?? ––
[17] 58/65 AV ?? ?
[18]4 0 C O A V ? ––
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123RCT was found (an RCT on deep brain stimulation in 11
patients with chronic cluster headache [31]). In the other
(non-headache) journals, I found 16 abstracts of RCTs on
headache and migraine [32–47].
The number of patients in each RCT varied from 27
to 1,981 with a median of 180 subjects. Percentage
response or absolute values for response were reported in
35 of 46 abstracts (Tables 2, 3, 4) and p values were
reported in 33 of 43 abstracts (Tables 2, 3, 4). In con-
trast, effect size and its precision (95% CI) were only
reported in the abstract of one RCT in Cephalalgia [16]
and Headache [25]. In other (non-headache) journals,
effect size with 95% CI was presented in ﬁve abstracts
[34–37, 44] (Table 4).
Table 3 Presentation in
abstracts concerning efﬁcacy in
double-blind, RCTs in
Headache in 2009 and 2010
CO crossover










[19] 177/169 ?? - -
[20] 688/696 AV ?- -
[21] 99/96 ?? - -
[22] (52) -- - -
2009
[23] 19/17 ?? - -
[24] (179) AV ?- -
[25] 153/153 ?? - -
[26] 121 CO ?? ? ?
[27] (283) ?? - -
[28] (180) AV ?- -
[29] (69) ?? - -
[30] (323) ?? - -
[31] (60) ?? - -
Table 4 Presentation in
abstracts concerning efﬁcacy in
double-blind, RCTs in other
(non-headache) journals in 2009
and 2010
CO crossover
a Mean and 95% CI for changes
from baseline










[33] 133 CO AV ?- -
[34]4 6 C O A V ?? ?
[35] 53/55/55/65 AV -?
a ?
a
[36] (196) AV -? ?
[37] 82/82 ?? ? ?
[38] (66) AV -? ?
[39] (265) ?? - -
2009
[40] 117/381/371/365 -? - -
[41] 29/49 AV ?- -
[42] (127) AV ?- -
[43]3 1 C O ?- - -
[44] 311/310 ?- - -
[45] 172/159 AV ?? ?
[46] -- ? - -
[47] 35/35/33 ?- - -
[48] 50/50 -- - -
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The number of patients treated in each RCT varied from
relatively small crossover trials (minimum, n = 27 trials
[11] was, however, a parallel-group trial) to very large
parallel-group trials (maximum, n = 1981). The median
was 180 patients, most likely a reasonable number.
In eight papers on RCTs, there was no mention in the
abstract of response either in percentages or in absolute
values [2–4, 12, 22, 40, 46, 48]. Two of these abstracts
were remarkable [3, 40]. One was a very large RCT in
which 1,677 patients were treated for[1 attack and 1,263
were treated for all 4 attacks [3]. Based on attack I data,
telcagepant 140 and 280 mg were signiﬁcantly (p\0.001)
more effective than placebo for 2-h pain freedom and six
other efﬁcacy measures [3]. In the other RCT (n = 1,234)
with different doses of telcagepant and placebo, only
p values (p\0.001) were given [39]. These abstracts
would not have been made much longer by reporting the
responses, e.g. 24 and 25% 2-h pain freedom for telcage-
pant versus 10 and 11% pain freedom for placebo [3, 39].
p values are traditionally used in reporting the results of
RCTs and were used in most abstracts. These p values can,
however, be very small if in a very large RCT there is a
small but clinically insigniﬁcant difference between two
treatments. p values can thus sometimes be misleading.
There is generally little reporting of effect size and its
precision, which was only presented in seven abstracts [17,
26, 34, 36–38, 45]. Effect size (active minus control) in
percentages or absolute value, with 95% conﬁdence inter-
vals (CI), is the clinically relevant measure. It is also useful
in ‘‘negative’’ RCTs where 95% CI (and not p values) gives
the precision of the comparability. Reporting of outcome
measures in the abstracts of the 43 papers is thus not
optimal when compared with the CONSORT statement for
reporting in abstracts [1].
In the latest CONSORT statement from 2010, for efﬁ-
cacy measures with binary outcomes it is recommended
that both absolute and relative effect sizes should be pre-
sented with an estimate of the precision such as 95% CI
[48, 49]. The relative risk (active/placebo) is 1.5 (25%/
10%) for pain freedom at 2 h for telcagepant 280 mg and
the odds ratio is 3.0 [3]. Relative risk and odds ratio [2] are
thus difﬁcult to judge clinically. One should be content
with reporting effect size and its precision in abstracts of
RCTs on migraine and headache. For example, the effect
size for telcagepant 280 mg for pain freedom at 2 h should
be reported as 15 with 95% CI: 10–19% [3].
In conclusion, the CONSORT statement from 2008 on
reporting RCT in abstracts [1] has only had a minor impact
on the headache literature in 2009 and 2010.
Conﬂict of interest None.
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